This trial is studying a combination of drugs to treat mantle cell lymphoma that has come back or does not respond to treatment. The drugs are polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human.
- Mantle Cell Lymphoma
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma
- Follicular Lymphoma Grade 2 (FL2)
- Refractory Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma (SLL)
1 Primary · 5 Secondary · Reporting Duration: Up to 5 years
1 Treatment Group
Treatment (rituximab, polatuzumab vedotin, venetoclax)
1 of 1
63 Total Participants · 1 Treatment Group
Primary Treatment: Rituximab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the precedent for Rituximab's efficacy?
"Rituximab is being trialed in 130 Phase 3 clinical trials, 656 studies in total. The medication is being tested at 24017 locations worldwide, with the majority of these sites based in Edmonton, Alberta." - Anonymous Online Contributor
How many people are allowed to participate in this test phase of the treatment?
"This clinical trial needs 63 eligible participants. The inclusion criteria for this study are specified on the website. Those who meet these qualifications and live near either Laura and Isaac Perlmutter Cancer Center at NYU Langone in New York, New York or University of Pennsylvania Abramson Cancer Center in Philadelphia, Pennsylvania are encouraged to apply." - Anonymous Online Contributor
What is the primary indication for Rituximab?
"Rituximab is an effective treatment for patients suffering from inflammatory breast cancer (IBC), b-cell lymphomas, and polyangiitis." - Anonymous Online Contributor
Are there any geographical restrictions to participating in this research?
"There are 7 sites recruiting patients for this study, including the Laura and Isaac Perlmutter Cancer Center at NYU Langone in New York, University of Pennsylvania Abramson Cancer Center in Philadelphia, Mayo Clinic in Rochester in Rochester, as well as other locations." - Anonymous Online Contributor
Are people still being recruited to participate in this trial?
"Yes, this is an ongoing study that is currently recruiting patients. The trial was first posted on 4/1/2021 and was most recently edited on 8/25/2022. The study is looking for 63 participants between 7 sites." - Anonymous Online Contributor
Has Rituximab been federally sanctioned for medical use?
"Rituximab's safety has been studied to some extent, but there is no data indicating that it is an effective treatment. Consequently, it received a score of 2." - Anonymous Online Contributor